A carregar...

Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases

BACKGROUND: Benralizumab, a humanized, afucosylated, monoclonal antibody that targets interleukin-5 receptor α, depletes eosinophils and basophils by enhanced antibody-dependent cell-mediated cytotoxicity. It demonstrated efficacy for patients with moderate to severe asthma and, in a Phase IIa trial...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Respir Res
Main Authors: Sridhar, Sriram, Liu, Hao, Pham, Tuyet-Hang, Damera, Gautam, Newbold, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6339432/
https://ncbi.nlm.nih.gov/pubmed/30658649
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-018-0968-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!